Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
about
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate TherapiesUnderstanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease ProgressionMicro-computed tomography derived anisotropy detects tumor provoked deviations in bone in an orthotopic osteosarcoma murine model.Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogsBiomarkers in Osteosarcoma.Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylationStrategies for the targeted delivery of therapeutics for osteosarcoma.Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology GroupChemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastasesmiR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.The Current and Future Therapies for Human Osteosarcoma.VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cellsHighlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.Diagnostic and prognostic sarcoma signatures.The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.Animal models of osteosarcoma.Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.Epigenetic alterations in osteosarcoma: promising targets.The immunotherapy of canine osteosarcoma: a historical and systematic review.Protein kinase C epsilon and genetic networks in osteosarcoma metastasis.Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species.miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing.
P2860
Q26782646-F36032E8-4835-4CD9-B15F-BC04ADDD1FF0Q26829949-6B6B2E34-DFEC-484B-893B-9AB64FBC8687Q33706492-D635E4B0-E7CB-43EE-A697-CE5AEB1B2593Q33926491-43F1B8A1-F500-49E3-AF26-AAE8BABBB18AQ33929072-BC36C0C9-13B2-4958-89CF-A1F117DB726EQ34087916-9EF25958-1677-4325-80AA-1B845E6CEAA3Q34179495-2516645E-695B-4D5D-BC6C-D34933160817Q34337703-A107E074-9DC2-4AF3-A960-DB63A893DFB3Q34700290-533D5B75-41B0-476B-AE35-2CDFB4D026E6Q35054920-E8B33A5D-7B7A-403B-B852-B4FC049694AFQ35097949-2AEE233D-D83E-46C5-B3B1-7CECB3152CB0Q35106102-44C561EE-E034-4E37-B1FB-2C5D3931A5C2Q35783986-962DA489-E61F-4C8E-A3FC-B71E5626EABEQ36211428-5ABAC68E-82D7-463E-A47A-FE3D7EE697C8Q36514299-211D7C62-813C-486F-B16D-A871322976F1Q36925606-DE88E426-754C-41A5-8FFD-28CE1043CB5EQ37271276-A1BC8811-0C24-40E5-A6C8-E8BD0B8B8A2CQ37324303-9F823238-C8E2-4CC2-889D-DDA971985B89Q37335373-8080F609-4D7B-43CE-81C9-4B5E09E5C022Q37427549-B5FD3FCF-4D9A-49F7-B544-B40A08B2F90DQ37782099-725CD30F-5978-47EB-9E28-D4591B1ECAD0Q37860966-6FD7762B-6564-4B6C-95BD-32F2CE7F9056Q38185555-2474B8C6-9708-422F-9929-6E2830E51C79Q38451770-CE5EF4D2-7194-4348-A48F-5A3D689F378FQ42265507-98FD0B7D-579B-4CB2-9A43-98C72174B344Q44077895-0667E4E7-7F06-4038-A38F-A593F981E295Q47699115-99B0BA2A-97F4-410F-8EB9-0C7720A8043EQ52722150-987AB400-5B54-4556-B6BB-8C3B0044078C
P2860
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@ast
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@en
type
label
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@ast
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@en
prefLabel
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@ast
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@en
P2093
P2860
P1476
Corruption of the Fas pathway ...... effect of aerosol gemcitabine.
@en
P2093
Arnulfo Mendoza
Chand Khanna
Eugenie S Kleinerman
Laura L Worth
Nadezhda V Koshkina
Nancy Gordon
Shu-Fang Jia
P2860
P304
P356
10.1158/1078-0432.CCR-07-0313
P407
P433
P577
2007-08-01T00:00:00Z